[Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Imatinib mesylate has significantly improved the outcome of patients with CML. In the IRIS trial, major molecular response (MMR), which is defined as the achievement of > or =3 log reduction in bcr-abl mRNA from the standardized baseline, was observed in 40% of CML patients by 12 months. Achievement of an MMR at 18 months is associated with 100% probability of transformation-free survival at 60 months, and MMR is an important goal of therapy. The nucleic acid quantitative "DNA probe FR Amp-CML" kit based on the transcription-mediated amplification method, can measure major bcr-abl mRNA in peripheral blood leukocytes. In this study, we studied the clinical usefulness of Amp-CML for monitoring minimum residual disease by comparison with the European standard nucleic acid quantitative method and real-time quantitative PCR (RQ-PCR) with GAPDH as an internal control, using peripheral leukocytes obtained from patients receiving imatinib treatment. The results indicated that Amp-CML had a significant correlation with Fusion Quant M-BCR (R>0.971, P<0.01), a standard nucleic acid quantitative method used in Europe and RQ-PCR (R>0.974, P<0.01), especially in samples with more than 100 copies/microg RNA of major bcr-abl mRNA. These data suggest that Amp-CML is reliable for monitoring major bcr-abl mRNA in patients having achieved an MMR.
Yagasaki
Fumiharu
F
Department of Hematology, Saitama Medical University International Medical Center.
Niwa
Toshihiro
T
Abe
Aki
A
Ishikawa
Maho
M
Kato
Chiaki
C
Ogura
Kenji
K
Sasaki
Hiroshi
H
Kyo
Taiichi
T
Jinnai
Ituroh
I
Bessyo
Masami
M
Miyamura
Kouichi
K
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000097:blood; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D007962:Leukocytes / Q000378:metabolism; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D010879:Piperazines / Q000627:therapeutic use; D016133:Polymerase Chain Reaction / Q000379:methods; D011743:Pyrimidines / Q000627:therapeutic use; D012333:RNA, Messenger / Q000097:blood*; D011933:Reagent Kits, Diagnostic
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D011933:Reagent Kits, Diagnostic; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl